(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX), a biopharmaceutical company focused on the development and commercialization of novel therapeutic products for tissue and organ protection, repair and regeneration, announced today that affiliates of the Company’s largest stockholder, Sigma-Tau Group, have purchased $950,000 of the Company’s common stock, and a new institutional investor, Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln Park”), has purchased $500,000 of the Company’s common stock. All shares were purchased at $0.27 per share, a 35% premium over the previous day’s closing price. In connection with these purchases, the Company issued to the purchasers common stock warrants to purchase 40% of the number of shares purchased, or an aggregate of 2,148,148 shares, at an exercise price of $0.38 per share over a five-year period. The transactions closed on January 7, 2011.
